Prelude Capital Management, LLC Guardant Health, Inc. Transaction History

Prelude Capital Management, LLC

$1.12 Billion
Q3 2025

A detailed history of Prelude Capital Management, LLC transactions in Guardant Health, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 27,492 shares of GH stock, worth $2.59 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

27,492

Previous 25,016 9.9%

Holding current value

$2.59 Million

Previous $1.3 Million 31.98%

% of portfolio

0.15%

Previous 0.14%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$40.98 - $67.42 $101,466 - $166,931	2,476 Added 9.9%	27,492 $1.72 Million
Q2 2025 Aug 14, 2025	BUY	$37.05 - $52.04 $259 - $364	7 Added 0.03%	25,016 $1.3 Million
Q1 2025 May 15, 2025	SELL	$31.77 - $49.94 $546,158 - $858,518	-17,191 Reduced 40.74%	25,009 $1.07 Million
Q4 2024 Feb 14, 2025	BUY	$20.2 - $38.11 $486,820 - $918,451	24,100 Added 133.15%	42,200 $1.29 Million
Q3 2024 Nov 14, 2024	SELL	$22.3 - $36.29 $35,969 - $58,535	-1,613 Reduced 8.18%	18,100 $415,000

Q2 2024 Aug 14, 2024	SELL	$16.07 - $31.84 $65,935 - $130,639	-4,103 Reduced 17.23%	19,713 $569,000
Q1 2024 May 15, 2024	BUY	$17.13 - $26.91 $407,968 - $640,888	23,816 New	23,816 $491,000
Q3 2023 Nov 14, 2023	BUY	$25.8 - $39.97 $221,880 - $343,742	8,600 New	8,600 $254,000
Q4 2022 Feb 14, 2023	SELL	$25.44 - $59.78 $120,560 - $283,297	-4,739 Reduced 32.22%	9,967 $271,000
Q3 2022 Nov 14, 2022	SELL	$43.66 - $61.0 $54,007 - $75,457	-1,237 Reduced 7.76%	14,706 $792,000
Q2 2022 Aug 15, 2022	BUY	$28.82 - $77.35 $459,477 - $1.23 Million	15,943 New	15,943 $643,000
Q1 2022 May 16, 2022	SELL	$48.25 - $100.49 $252,154 - $525,160	-5,226 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$88.71 - $120.43 $146,903 - $199,432	1,656 Added 46.39%	5,226 $523,000
Q3 2021 Nov 15, 2021	SELL	$98.77 - $132.17 $330,978 - $442,901	-3,351 Reduced 48.42%	3,570 $446,000
Q2 2021 Aug 16, 2021	BUY	$109.77 - $165.68 $517,126 - $780,518	4,711 Added 213.17%	6,921 $860,000
Q1 2021 May 17, 2021	SELL	$127.04 - $179.1 $585,400 - $825,292	-4,608 Reduced 67.59%	2,210 $337,000
Q4 2020 Feb 16, 2021	BUY	$99.96 - $135.93 $109,756 - $149,251	1,098 Added 19.2%	6,818 $879,000
Q3 2020 Nov 16, 2020	BUY	$80.32 - $111.8 $166,262 - $231,426	2,070 Added 56.71%	5,720 $639,000
Q2 2020 Aug 14, 2020	BUY	$60.49 - $97.5 $177,598 - $286,260	2,936 Added 411.2%	3,650 $296,000
Q1 2020 May 15, 2020	BUY	$59.04 - $88.81 $42,154 - $63,410	714 New	714 $50,000
Q4 2019 Feb 14, 2020	SELL	$59.49 - $82.78 $654 - $910	-11 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$62.59 - $110.3 $86,937 - $153,206	-1,389 Reduced 99.21%	11 $1,000
Q2 2019 Aug 14, 2019	SELL	$63.94 - $91.11 $133,570 - $190,328	-2,089 Reduced 59.87%	1,400 $121,000
Q1 2019 May 15, 2019	SELL	$34.3 - $97.98 $190,536 - $544,278	-5,555 Reduced 61.42%	3,489 $268,000
Q4 2018 Feb 14, 2019	BUY	$29.2 - $46.1 $264,084 - $416,928	9,044 New	9,044 $340,000

Others Institutions Holding GH

# of Institutions

450

Shares Held

125M

Call Options Held

2.18M

Put Options Held

2.69M

View Full List

About Guardant Health, Inc.

Ticker GH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 102,220,000
Market Cap $9.65B
Description
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...

More about GH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Account

Prelude Capital Management, LLC Guardant Health, Inc. Transaction History